Internship

Intern – Clinical Operations

Posted on 11/30/2023

Denali Therapeutics

Denali Therapeutics

201-500 employees

Develops treatments for neurodegenerative diseases

Compensation Overview

$20.96 - $25.87/hr

San Bruno, CA, USA

Required Skills
Communications
Requirements
  • Candidates pursuing a BS degree in a scientific discipline
  • Self- and results-driven, organized, resourceful, adaptable and collaborative
  • Bold and creative thinker with a curious nature, eager to learn about the complexities of the business of healthcare and biotech
  • Evident communication and analytical skills
  • High degree of proficiency with the MS Office Suite or Google equivalent
  • Strong organizational skills, critical thinking and ability to juggle multiple projects
  • Experience with Good Documentation Practice (GCP), records management and/or the TMF Reference Model is preferred
Responsibilities
  • Assist with filing and reconciliation of clinical trial documentation
  • Track, maintain, and perform quality check of study documents
  • Support clinical study teams with ongoing oversight of the Trial Master File (TMF) by ensuring documents meet GxP standards
  • Communicate with cross-functional study team members and external partners to ensure appropriate management of the TMF
  • Identify gaps and escalate quality issues to the clinical operations study lead
  • Participate in the development of TMF tools and processes, including SOPs, work instructions, templates and other applicable reference materials

Denali Therapeutics focuses on developing treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, which involve the gradual loss of nerve cells leading to serious health issues. The company uses scientific research to understand the biological pathways that cause these diseases, aiming to create drugs that target specific molecules in the body. Denali stands out from competitors by combining its own research efforts with partnerships with other biotech firms and pharmaceutical companies, allowing for shared resources and knowledge. The goal of Denali Therapeutics is to create effective treatments that improve the lives of patients suffering from these debilitating conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Denali opened a new biomanufacturing facility in Salt Lake City in October 2023.
  • The company secured $500 million in private placement equity financing in October 2023.
  • Denali's spinout, Tenvie Therapeutics, raised $200 million, reflecting strategic R&D shifts.

What critics are saying

  • SAR443820/DNL788 failed in the Phase II HIMALAYA trial for ALS.
  • Denali faces increased competition with over 100 ALS treatment candidates.
  • Previous RIPK1 inhibitors showed toxicities, raising safety concerns for current candidates.

What makes Denali Therapeutics unique

  • Denali focuses on neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS.
  • The company employs a science-driven approach to translational medicine and clinical development.
  • Denali leverages strategic partnerships to access new technologies and scientific insights.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-4%

2 year growth

-2%
Tech Buzz News
Mar 29th, 2025
Denali Therapeutics Opens New Biomanufacturing Facility in Salt Lake City

Denali Therapeutics opens new biomanufacturing facility in Salt Lake City.

Defense World
Mar 10th, 2025
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)

Proficio Capital Partners LLC makes new $514,000 investment in Denali Therapeutics Inc. (NASDAQ:DNLI).

Stat News
Jan 8th, 2025
Denali Therapeutics spinout raises $200M as neuro company resets

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates.

BioSpace
Mar 4th, 2024
ALS Treatment Landscape 'Primed' with Over 100 Candidates: GlobalData

Last month, Sanofi and development partner Denali Therapeutics announced that their ALS hopeful SAR443820/DNL788, an investigational RIPK1 blocker, could not significantly improve functional performance in the Phase II HIMALAYA trial.

ForexTV
Feb 27th, 2024
Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics announces $500 million private placement equity financing.

INACTIVE